Gastrointestinal transit in the chicken was investigated by using 198Au-colloid as a marker. Gastrointestinal transit was determined following administration of a 198Au-colloid solution (370 kBq (10 microCi), 0.5 ml) into the proventriculus by measuring the distribution of radioactivity in the gastrointestine. Most of 198Au-colloid administered into the proventriculus was transferred instantly to the gizzard and subsequently, some part of it quickly to the duodenum and the upper segment of the jejunoileum. A considerable quantity of 198Au-colloid in the duodenum, the upper and middle segment of the jejunoileum regurgitated to the gizzard. 198Au-colloid transferred to the caecum was retained for a long time (more than 48 hours) in these segments. A part of 198Au-colloid was found in the feces 90 to 120 minutes after administration into the proventriculus and the greater part of it was excreted into the feces 24 to 48 hours. Subcutaneous administration of acetylcholine (2 mg/kg) increased the gastrointestinal transit but atropine (2 mg/kg) decreased.

Download full-text PDF

Source

Publication Analysis

Top Keywords

gastrointestinal transit
12
transit chicken
8
198au-colloid marker
8
duodenum upper
8
segment jejunoileum
8
198au-colloid
7
[gastrointestinal transit
4
chicken 198au-colloid
4
marker author's
4
author's transl]
4

Similar Publications

Children with neurodegenerative disease often have debilitating gastrointestinal symptoms. We hypothesized that this may be due at least in part to underappreciated degeneration of neurons in the enteric nervous system (ENS), the master regulator of bowel function. To test this hypothesis, we evaluated mouse models of neuronal ceroid lipofuscinosis type 1 and 2 (CLN1 and CLN2 disease, respectively), neurodegenerative lysosomal storage disorders caused by deficiencies in palmitoyl protein thioesterase-1 and tripeptidyl peptidase-1, respectively.

View Article and Find Full Text PDF

Advanced polymeric systems for colon drug delivery: from experimental models to market applications.

Soft Matter

January 2025

Department of Chemical Materials and Industrial Production (DICMaPI), University of Naples Federico II, P.le Tecchio 80, Naples 80125, Italy.

In recent years, nano and micro drug delivery systems targeting the colon have gained more attention due to increasing interest in treating colon diseases such as colorectal cancer and inflammatory bowel disease, , Crohn's disease and ulcerative colitis. Usually, nanocarriers are exploited for their enhanced permeability properties, allowing higher penetration effects and bioavailability, while microcarriers are primarily used for localized and sustained release. In bowel diseases, carriers must go into a delicate environment with a strict balance of gut bacteria (, colon), and natural or biodegradable polymers capable of ensuring lower toxicity are preferred.

View Article and Find Full Text PDF

Colon cancer is a leading cause of cancer-related morbidity and mortality worldwide, necessitating advancements in therapeutic strategies to improve outcomes. Current treatment modalities, including surgery, chemotherapy, and radiation, are limited by systemic toxicity, low drug utilization rates, and off-target effects. Colon-targeted drug delivery systems (CDDS) offer a promising alternative by leveraging the colon's unique physiology, such as near-neutral pH and extended transit time, to achieve localized and controlled drug release.

View Article and Find Full Text PDF

Background: The relationship between gut microbiota composition, lifestyles, and colonic transit time (CTT) remains poorly understood. This study investigated associations among gut microbiota profiles, diet, lifestyles, and CTT in individuals with subjective constipation.

Methods: We conducted a secondary analysis of data from our randomized clinical trial, examining gut microbiota composition, CTT, and dietary intake in baseline and final assessments of 94 participants with subjective constipation.

View Article and Find Full Text PDF

Feasibility and complications of videocapsule endoscopy in dogs weighing 7 kg or less.

J Vet Intern Med

January 2025

Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.

Background: Videocapsule endoscopy (VCE) is a valuable tool for investigating gastrointestinal (GI) diseases in dogs. Its use is not recommended in dogs ≤4.3 kg, because of risks of GI endoscopic capsule (EC) retention and bowel obstruction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!